Equities

Enseval Putera Megatrading Tbk PT

Enseval Putera Megatrading Tbk PT

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (IDR)3,000.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change11.11%
  • Beta0.5398
Data delayed at least 10 minutes, as of Apr 13 2017 08:57 BST.
More ▼

Profile data is unavailable for this security.

About the company

PT Enseval Putera Megatrading Tbk is an Indonesia-based company primarily engaged in distributing and trading pharmaceutical and consumer products. Its business is classified into three operating segments: pharmaceutical products, consumer products and others. The pharmaceutical products segment includes the distribution of prescription drugs and over-the-counter (OTC) drugs, while the consumer products segment comprises the distribution of nutritional products and other consumer products. Its others segment includes the distribution of medical equipment, veterinary products and raw materials for pharmaceutical industry as well as the provision of health care services. Its subsidiaries include PT Tri Sapta Jaya, which distributes pharmaceutical and health care products; PT Millenia Dharma Insani, which operates clinics under the brand name of Mitrasarana, and PT Enseval Medika Prima, which distributes medical equipment.

  • Revenue in IDR (TTM)18.75tn
  • Net income in IDR535.89bn
  • Incorporated1989
  • Employees5.44k
  • Location
    Enseval Putera Megatrading Tbk PTJl. Pulo Lentut No. 10Kawasan Industri Pulo GadungJAKARTA TIMUR 13920IndonesiaIDN
  • Phone+62 2 146822422
  • Fax+62 214609039
  • Websitehttp://www.enseval.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirtex Medical Limited232.68m48.45m853.91m279.0017.774.2515.533.670.83280.83284.003.480.967218.825.42833,985.7020.1420.8723.1625.1584.4783.7520.8221.354.69--0.0031.9532.0327.0332.8136.0915.8833.78
Shanghai Jiaoda Onlly Co., Ltd277.65m156.41m4.63bn610.0024.672.83--16.660.24030.24030.41882.100.11561.794.38455,169.805.294.127.215.0959.7863.6245.7823.830.595--0.227551.50-30.92-4.5717.0011.35-20.887.39
Consun Pharmaceutical Group Ltd1.38bn347.29m5.22bn1.30k14.812.6312.903.780.3620.3621.442.040.52322.952.60--13.6714.6317.7617.9774.4677.3926.1328.042.28----21.7647.2125.7423.1623.44----
Healios KK77.64m-3.43bn69.29bn58.00--11.27--892.39-84.41-84.411.91146.500.0079--3.811,338,621.00-34.92---38.56--88.22---4,422.40-----100.390.2943---20.91---258.37------
Enseval Putera Megatrading Tbk PT18.75tn535.89bn8.13tn5.44k15.161.8312.290.4335197.84197.846,920.791,641.102.777.848.343,319,039,000.007.918.7412.5815.3711.3311.382.863.071.48--0.01612.022.7312.467.0616.283.81-28.71
Industri Jamu dan Farmasi Sd Mncl Tbk PT2.46tn463.37bn8.25tn4.40k17.333.1815.223.3531.7431.74168.47173.220.88574.966.59592,383,400.0016.6918.1817.9222.0841.4439.6418.8417.476.32--0.00--0.93863.524.7813.0315.32--
Data as of Apr 13 2017. Currency figures normalised to Enseval Putera Megatrading Tbk PT's reporting currency: Indonesian Rupiah IDR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.